Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, B-Cell 1Lymphoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 160Rituximab 82Peripheral Blood Stem Cell Transplantation 78fludarabine phosphate 75Etoposide 69Filgrastim 67Methotrexate 59Cytarabine 58Vincristine 50Mycophenolic Acid 50Whole-Body Irradiation 48Radiotherapy 43Cyclosporine 43Busulfan 42Tacrolimus 40Melphalan 39Dexamethasone 37Prednisone 36Doxorubicin 36Antilymphocyte Serum 36fludarabine 31blinatumomab 27Methylprednisolone 24Granulocyte Colony-Stimulating Factor 22Carmustine 22Cord Blood Stem Cell Transplantation 21Calcium Dobesilate 18CT-P10 18Inotuzumab Ozogamicin 16sargramostim 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Burkitt Lymphoma × brexucabtagene autoleucel × Clear all
NCT06144606 2026-03-31

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡